In agreement with previous reports indicating Akt as a target for the treatment of prostate cancer [28, 29], we also observed that knockdown of PSMC2 could decrease the activity of Akt pathway, especially the decline in its phosphorylation level. The gene discussed is PSMC2; the disease is prostate carcinoma.